Cocrystal Pharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2
- Today's High:
- $2.13
- Open Price:
- $2.05
- 52W Low:
- $1.74
- 52W High:
- $6.24
- Prev. Close:
- $2.09
- Volume:
- 19768
Company Statistics
- Market Cap.:
- $22.69 million
- Book Value:
- 4.257
- Revenue TTM:
- $510000
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-8794000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -21.03%
- Return on Equity TTM:
- -73.57%
Company Profile
Cocrystal Pharma Inc had its IPO on 2011-05-19 under the ticker symbol COCP.
The company operates in the Healthcare sector and Biotechnology industry. Cocrystal Pharma Inc has a staff strength of 12 employees.
Stock update
Shares of Cocrystal Pharma Inc opened at $2.05 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2 - $2.13, and closed at $2.
This is a -4.31% slip from the previous day's closing price.
A total volume of 19,768 shares were traded at the close of the day’s session.
In the last one week, shares of Cocrystal Pharma Inc have slipped by -28.06%.
Cocrystal Pharma Inc's Key Ratios
Cocrystal Pharma Inc has a market cap of $22.69 million, indicating a price to book ratio of 0.4525 and a price to sales ratio of 92.4548.
In the last 12-months Cocrystal Pharma Inc’s revenue was $510000 with a gross profit of $-8794000 and an EBITDA of $-18855000. The EBITDA ratio measures Cocrystal Pharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cocrystal Pharma Inc’s operating margin was 0% while its return on assets stood at -21.03% with a return of equity of -73.57%.
In Q1, Cocrystal Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 26.9%.
Cocrystal Pharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-4.94 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cocrystal Pharma Inc’s profitability.
Cocrystal Pharma Inc stock is trading at a EV to sales ratio of 17.8912 and a EV to EBITDA ratio of 0.577. Its price to sales ratio in the trailing 12-months stood at 92.4548.
Cocrystal Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $37.84 million
- Total Liabilities
- $3.15 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $45000
- Dividend Payout Ratio
- 0%
Cocrystal Pharma Inc ended 2024 with $37.84 million in total assets and $0 in total liabilities. Its intangible assets were valued at $37.84 million while shareholder equity stood at $34.67 million.
Cocrystal Pharma Inc ended 2024 with $0 in deferred long-term liabilities, $3.15 million in other current liabilities, 8000.00 in common stock, $-303119000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $33.98 million and cash and short-term investments were $33.98 million. The company’s total short-term debt was $208,000 while long-term debt stood at $0.
Cocrystal Pharma Inc’s total current assets stands at $37.24 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $956000.00 compared to accounts payable of $2.65 million and inventory worth $0.
In 2024, Cocrystal Pharma Inc's operating cash flow was $0 while its capital expenditure stood at $45000.
Comparatively, Cocrystal Pharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2
- 52-Week High
- $6.24
- 52-Week Low
- $1.74
- Analyst Target Price
- $9.67
Cocrystal Pharma Inc stock is currently trading at $2 per share. It touched a 52-week high of $6.24 and a 52-week low of $6.24. Analysts tracking the stock have a 12-month average target price of $9.67.
Its 50-day moving average was $2.65 and 200-day moving average was $2.42 The short ratio stood at 0.84 indicating a short percent outstanding of 0%.
Around 2504.9% of the company’s stock are held by insiders while 1309.3% are held by institutions.
Frequently Asked Questions About Cocrystal Pharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.